Reuters: Regulatory News: FDA staff question Pfizer arthritis drug benefits

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA staff question Pfizer arthritis drug benefits May 7th 2012, 12:36 WASHINGTON | Mon May 7, 2012 8:36am EDT WASHINGTON May 7 (Reuters) - U.S. drug reviewers questioned whether the benefits of Pfizer Inc's experimental treatment for rheumatoid arthritis outweighed its risks of cancerous cells and infections. The Food and Drug Administration staff said the drug, called tofacitinib, appeared to reduce swollen and tender joints during clinical trials, but questioned the method of using radiographs to prove the drug worked. The FDA staff review comes ahead of an advisory panel, which will vote on whether to recommend the drug on Wednesday. The FDA will make a final decision in August, taking into account the panel's recommendations.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions